首页> 外文期刊>Molecules >Identification of a Quality Marker (Q-Marker) of Danhong Injection by the Zebrafish Thrombosis Model
【24h】

Identification of a Quality Marker (Q-Marker) of Danhong Injection by the Zebrafish Thrombosis Model

机译:斑马鱼血栓形成模型鉴定丹红注射液的质量标记(Q标记)

获取原文
获取外文期刊封面目录资料

摘要

Quality-marker (Q-marker) is an emerging concept to ensure the quality and batch-to-batch consistency of Chinese medicine (CM). However, significant difficulties remain in the identification of Q-markers due to the unclear relationship between complex chemical compositions and the pharmacological efficacy of CM. In the present study, we proposed a novel strategy to identify the potential Q-marker of danhong injection (DHI) by an in vivo zebrafish thrombosis model. The anti-thrombotic effects of DHI and its major constituents were evaluated by the zebrafish model of arachidonic acid (AA)-induced thrombosis. The results indicated that DHI can attenuate tail venous thrombus and recover the decrease of heart red blood cell (RBC) intensity in a dose-dependent manner. The result that DHI prevented the formulation of thrombosis in zebrafish was also validated in the zebrafish thrombosis model with green fluorescence protein (GFP)-labeled hemoglobin. The major components of DHI, namely danshen (DS) and honghua (HH), as well as the major chemical constituents of DHI, also exerted anti-thrombotic effects, among which rosmarinic acid (RA) and p-coumaric acid (pCA) showed moderate anti-thrombotic effects. This is the first time that pCA from HH has been found as an active compound exerting an anti-thrombotic effect in a dose-dependent manner, whose IC 50 value is approximately 147 μg/mL. By analyzing 10 batches of normal DHI samples and five abnormal samples by high-performance liquid chromatography (HPLC), we found the contents of pCA and RA can be positively correlated to the anti-thrombotic effect of DHI, suggesting that pCA and RA could be potential Q-markers of DHI to ensure batch-to-batch consistency. Our findings illustrated that discovering major active compounds from CM by in vivo pharmacological models can be a useful approach to identifying Q-markers of CM, and in vivo pharmacological models can be a potential tool to evaluate batch-to-batch consistency of CMs.
机译:质量标记(Q标记)是一个新兴概念,可确保中药(CM)的质量和批次之间的一致性。但是,由于复杂的化学成分和CM的药理作用之间的关系不清楚,在鉴定Q标记方面仍然存在很大困难。在本研究中,我们提出了一种新的策略,通过体内斑马鱼血栓形成模型来鉴定丹红注射液(DHI)的潜在Q标记。 DHI及其主要成分的抗血栓形成作用通过花生四烯酸(AA)诱发的血栓形成的斑马鱼模型进行评估。结果表明,DHI可以减弱尾静脉血栓并恢复剂量依赖性的心脏红细胞(RBC)强度下降。 DHI阻止斑马鱼中血栓形成的结果在带有绿色荧光蛋白(GFP)标记的血红蛋白的斑马鱼血栓形成模型中也得到了验证。 DHI的主要成分,如丹参(DS)和红花(HH),以及DHI的主要化学成分,也具有抗血栓形成作用,其中迷迭香酸(RA)和对香豆酸(pCA)显示出中等的抗血栓形成作用。这是首次发现来自HH的pCA是一种以剂量依赖性方式发挥抗血栓形成作用的活性化合物,其IC 50值约为147μg/ mL。通过高效液相色谱(HPLC)分析10批正常DHI样品和5份异常样品,我们发现pCA和RA的含量与DHI的抗血栓形成作用呈正相关,表明pCA和RA可能是DHI的潜在Q标记,以确保批次之间的一致性。我们的发现表明,通过体内药理模型从CM中发现主要活性化合物可能是鉴定CM Q标记的有用方法,而体内药理模型则可能是评估CM批次间一致性的潜在工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号